Pages that link to "Item:Q3079026"
From MaRDI portal
The following pages link to A Measure of the Proportion of Treatment Effect Explained by a Surrogate Marker (Q3079026):
Displaying 27 items.
- Assessing the value of a censored surrogate outcome (Q118842) (← links)
- Causal measures of the treatment effect captured by candidate surrogate endpoints (Q887978) (← links)
- Linear increment in efficiency with the inclusion of surrogate endpoint (Q2339530) (← links)
- The identification of direct and indirect effects in studies with an unmeasured intermediate variable (Q2791838) (← links)
- A shrinkage approach for estimating a treatment effect using intermediate biomarker data in clinical trials (Q2893404) (← links)
- Meta-analysis for surrogacy: accelerated failure time models and semicompeting risks modeling (Q2894010) (← links)
- Bayesian inference for causal mediation effects using principal stratification with dichotomous mediators and outcomes (Q3305026) (← links)
- Improving efficiency in clinical trials using auxiliary information: Application of a multi‐state cure model (Q3459944) (← links)
- Bounds on Direct Effects in the Presence of Confounded Intermediate Variables (Q3530085) (← links)
- A Bayesian Approach to Surrogacy Assessment Using Principal Stratification in Clinical Trials (Q3576929) (← links)
- On Assessing Surrogacy in a Single Trial Setting Using a Semicompeting Risks Paradigm (Q3637000) (← links)
- Exploring the Relationship Between Surrogates and Clinical Outcomes: Analysis of Individual Patient Data vs. Meta-regression on Group-Level Summary Statistics (Q4430351) (← links)
- Model-free approach to quantifying the proportion of treatment effect explained by a surrogate marker (Q5222223) (← links)
- Semiparametric Inference for Surrogate Endpoints with Bivariate Censored Data (Q5450466) (← links)
- Equivalence between direct and indirect effects with different sets of intermediate variables and covariates (Q5963507) (← links)
- Evaluation of longitudinal surrogate markers (Q6050955) (← links)
- Evaluating multiple surrogate markers with censored data (Q6055488) (← links)
- Robust methods to correct for measurement error when evaluating a surrogate marker (Q6055522) (← links)
- Quantifying direct and indirect effect for longitudinal mediator and survival outcome using joint modeling approach (Q6055651) (← links)
- Proportion of treatment effect mediated by surrogate endpoints (Q6067311) (← links)
- Robust Approach to Combining Multiple Markers to Improve Surrogacy (Q6079767) (← links)
- Testing for Heterogeneity in the Utility of a Surrogate Marker (Q6079768) (← links)
- Quantifying the feasibility of shortening clinical trial duration using surrogate markers (Q6628174) (← links)
- Estimation of the proportion of treatment effect explained by a high-dimensional surrogate (Q6628359) (← links)
- Identifying surrogate markers in real-world comparative effectiveness research (Q6629372) (← links)
- Using a surrogate with heterogeneous utility to test for a treatment effect (Q6629910) (← links)
- Flexible evaluation of surrogate markers with Bayesian model averaging (Q6630321) (← links)
